|Mr. Richard A. Gonzalez||Chairman & CEO||7,11M||N/A||1954|
|Dr. Michael E. Severino||Vice Chairman & Pres||3,98M||N/A||1966|
|Mr. Robert A. Michael||Exec. VP & CFO||2,76M||N/A||1970|
|Ms. Laura J. Schumacher||Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.||4,3M||N/A||1963|
|Mr. Carlos Alban||Vice Chairman & Chief Commercial Officer||4,08M||N/A||1963|
|Dr. Azita Saleki-Gerhardt||Exec. VP of Operations||N/A||N/A||1963|
|Dr. Thomas J. Hudson||Sr. VP of R&D and Chief Scientific Officer||N/A||N/A||1962|
|Ms. Elizabeth Shea||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Timothy J. Richmond||Exec. VP & Chief HR Officer||N/A||N/A||1966|
|Mr. Scott C. Brun M.D.||VP of Scientific Affairs & Head of AbbVie Ventures||N/A||N/A||N/A|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Frontier Medicines, Corp.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
AbbVie Inc.s ISS Governance QualityScore, Stand 1. Dezember 2020, lautet 8. Die grundlegenden Scores sind Audit: 2, Vorstand: 7, Shareholderrechte: 9, Kompensation: 3.